254 related articles for article (PubMed ID: 26236939)
1. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
[TBL] [Abstract][Full Text] [Related]
2. Early drug development predictions of glass-forming ability and physical stability of drugs.
Mahlin D; Bergström CA
Eur J Pharm Sci; 2013 May; 49(2):323-32. PubMed ID: 23557841
[TBL] [Abstract][Full Text] [Related]
3. Correlating thermodynamic and kinetic parameters with amorphous stability.
Graeser KA; Patterson JE; Zeitler JA; Gordon KC; Rades T
Eur J Pharm Sci; 2009 Jun; 37(3-4):492-8. PubMed ID: 19394421
[TBL] [Abstract][Full Text] [Related]
4. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
Kawakami K; Usui T; Hattori M
J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
[TBL] [Abstract][Full Text] [Related]
5. Applying thermodynamic and kinetic parameters to predict the physical stability of two differently prepared amorphous forms of simvastatin.
Graeser KA; Patterson JE; Rades T
Curr Drug Deliv; 2009 Aug; 6(4):374-82. PubMed ID: 19534709
[TBL] [Abstract][Full Text] [Related]
6. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility.
Zhou D; Zhang GG; Law D; Grant DJ; Schmitt EA
J Pharm Sci; 2002 Aug; 91(8):1863-72. PubMed ID: 12115813
[TBL] [Abstract][Full Text] [Related]
7. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
8. Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs.
Nurzyńska K; Austin RP; Fischer PM; Booth J; Gommer F
J Pharm Sci; 2016 Jun; 105(6):1858-1866. PubMed ID: 27238485
[TBL] [Abstract][Full Text] [Related]
9. Effect of counterions on the properties of amorphous atorvastatin salts.
Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
[TBL] [Abstract][Full Text] [Related]
10. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp M; Milne M; Liebenberg W
AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
[TBL] [Abstract][Full Text] [Related]
11. Toward Developing a Predictive Approach To Assess Electron Beam Instability during Transmission Electron Microscopy of Drug Molecules.
S'ari M; Blade H; Brydson R; Cosgrove SD; Hondow N; Hughes LP; Brown A
Mol Pharm; 2018 Nov; 15(11):5114-5123. PubMed ID: 30212216
[TBL] [Abstract][Full Text] [Related]
12. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
Kuentz M; Imanidis G
Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
Trasi NS; Baird JA; Kestur US; Taylor LS
J Phys Chem B; 2014 Aug; 118(33):9974-82. PubMed ID: 25076138
[TBL] [Abstract][Full Text] [Related]
14. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine.
Baghel S; Cathcart H; Redington W; O'Reilly NJ
Eur J Pharm Biopharm; 2016 Jul; 104():59-71. PubMed ID: 27108783
[TBL] [Abstract][Full Text] [Related]
15. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
Marsac PJ; Li T; Taylor LS
Pharm Res; 2009 Jan; 26(1):139-51. PubMed ID: 18779927
[TBL] [Abstract][Full Text] [Related]
16. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
[TBL] [Abstract][Full Text] [Related]
17. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
18. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
[TBL] [Abstract][Full Text] [Related]
19. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
20. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.
Zhou D; Grant DJ; Zhang GG; Law D; Schmitt EA
J Pharm Sci; 2007 Jan; 96(1):71-83. PubMed ID: 17031846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
